肥満症治療薬市場：治療タイプ別、最終用途別-2025-2030年の世界予測

肥満症治療薬市場の2023年の市場規模は99億8,000万米ドルで、2024年には108億1,000万米ドルに達すると予測され、CAGR 8.44％で成長し、2030年には176億米ドルに達すると予測されています。

肥満症治療薬市場の範囲は、肥満と関連疾患に対処する医薬品と治療法の開拓、生産、販売です。この業界は、肥満率の上昇と、それに伴う糖尿病、心血管疾患、特定のがんなどの健康合併症によって引き起こされる世界の肥満の流行と闘う必要性の高まりによって定義されます。肥満症治療薬の必要性は、肥満が健康に及ぼす影響に対する意識の高まり、ヘルスケアコストの増加、体重管理をターゲットとした公衆衛生上の取り組みに起因しています。その用途には医薬品、栄養補助食品、ライフスタイルへの介入が含まれ、エンドユーザーはヘルスケアプロバイダーやフィットネスセンターから減量ソリューションを求める個人消費者まで多岐にわたる。この市場に影響を与える主な成長要因には、医薬品開発における技術的進歩、ヘルスケア革新に対する政府のインセンティブ、研究開発投資の増加などがあります。さらに、バイオテクノロジーの進歩の急増や、体重管理のための医薬品介入に対する消費者の受け入れの拡大も市場を後押ししています。

世界的に肥満の有病率が増加しており、より効果的で安全な治療に対する需要が高まっていることから、潜在的なビジネスチャンスが生じています。企業は、特定の遺伝子プロファイルに合わせた新規治療薬や個別化医療アプローチを開発することで、こうした機会を活用することができます。しかし、厳しい規制要件、研究開発コストの高さ、抗肥満薬に伴う副作用の可能性といった限界や課題に直面しており、これがより広範な採用の妨げとなっています。革新的な分野としては、体重管理効果のある天然成分の探索、肥満における腸内細菌叢の役割の研究、有効性の向上と副作用の軽減を目的とした併用療法の推進などが挙げられます。市場の発展に伴い、肥満率を高める人口動態やライフスタイルの変化を経験している新興市場への進出は、企業にとって有益です。この競合情勢において、研究機関やヘルスケアプロバイダーとの共同研究やパートナーシップは、課題を克服しイノベーションを促進する上で極めて重要です。市場動向や消費者行動を把握することで、企業はこのダイナミックな分野を効果的にナビゲートできるようになります。

市場力学：急速に進化する肥満症治療薬市場における重要な市場洞察の解明

肥満症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肥満および関連疾患の増加
  • 運動不足による座りがちなライフスタイルの増加
  • 新規抗肥満薬のイントロダクション
• 市場抑制要因
  • 精神疾患や脳卒中など、肥満症治療薬の副作用のリスク
• 市場機会
  • 進行中の臨床試験および研究開発活動
  • 臨床的に有意な体重減少に関連する薬剤ターゲットの増加
• 市場の課題
  • 体重管理に関する知識の不足

ポーターのファイブフォース：肥満症治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肥満症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、肥満症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肥満症治療薬市場における競合情勢の把握

肥満症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肥満症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肥満症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肥満症治療薬市場における成功への道筋を描く

肥満症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肥満および関連疾患の発生率の増加
    • 運動不足による座りっぱなしの生活習慣の増加
    • 新規抗肥満薬のイントロダクション
  • 抑制要因
    • 精神障害や脳卒中などの肥満症治療薬の副作用のリスク
  • 機会
    • 進行中の臨床試験および研究開発活動
    • 臨床的に有意な体重減少に関連する薬物ターゲットの増加
  • 課題
    • 体重管理に関する知識が限られている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肥満症治療薬市場治療の種類別

• 医薬品
  • ブプロピオン-ナルトレキソン
  • リラグルチド
  • オルリスタット
  • フェンテルミン-トピラマート
  • セマグルチド
• 治療
  • 調節性胃バンディング
  • 内視鏡的スリーブ胃形成術
  • 胃バイパス手術

第7章 肥満症治療薬市場：最終用途別

• 外来手術センター
• 病院
• 専門クリニック

第8章 南北アメリカの肥満症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の肥満症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの肥満症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Currax Pharmaceuticals LLC
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Norgine B.V.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• SHIONOGI & Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Vivus LLC

LIST OF FIGURES

• FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 61. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 62. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 65. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 66. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 134. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 135. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 151. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 154. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 155. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 192. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Anti-Obesity Therapeutics Market was valued at USD 9.98 billion in 2023, expected to reach USD 10.81 billion in 2024, and is projected to grow at a CAGR of 8.44%, to USD 17.60 billion by 2030.

The scope of the anti-obesity therapeutics market involves developing, producing, and marketing drugs and treatments that address obesity and related conditions. This industry is defined by a growing need to combat the global obesity epidemic, driven by rising obesity rates and associated health complications such as diabetes, cardiovascular diseases, and certain cancers. The necessity for anti-obesity therapeutics stems from heightened awareness of obesity's health effects, increased healthcare costs, and public health initiatives targeting weight management. Its application includes pharmaceuticals, dietary supplements, and lifestyle interventions, with end-users ranging from healthcare providers and fitness centers to individual consumers seeking weight loss solutions. Key growth factors influencing this market include technological advancements in drug development, government incentives for healthcare innovation, and increased investment in research and development. Additionally, the market is buoyed by a surge in biotechnology advancements and growing consumer acceptance of pharmaceutical interventions for weight management.

Potential opportunities arise from the increasing prevalence of obesity worldwide, driving demand for more effective and safer treatments. Companies can capitalize on these opportunities by developing novel therapeutics and personalized medicine approaches tailored to specific genetic profiles. However, the market faces limitations and challenges, such as stringent regulatory requirements, high R&D costs, and potential side effects associated with anti-obesity drugs, which hinder broader adoption. Innovation areas include exploring natural ingredients with weight management benefits, investigating the role of gut microbiome in obesity, and advancing combination therapies to enhance efficacy and reduce side effects. As the market evolves, businesses can benefit from expanding into emerging markets experiencing demographic and lifestyle changes driving obesity rates. In this competitive landscape, collaborations and partnerships with research institutions and healthcare providers are crucial to overcoming challenges and fostering innovation. Insights into market trends and consumer behavior will enable companies to navigate this dynamic sector effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Therapeutics Market

The Anti-Obesity Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of obesity and related disorder
  • Rising adoption of sedentary lifestyle due to lack of exercise
  • Introduction of novel anti-obesity drugs
• Market Restraints
  • Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
• Market Opportunities
  • Ongoing clinical trials and research & development activities
  • Increasing number of drug targets associated with clinically significant weight loss
• Market Challenges
  • Limited of knowledge regarding weight management

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Therapeutics Market

A detailed market share analysis in the Anti-Obesity Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Therapeutics Market

A strategic analysis of the Anti-Obesity Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Medications and Treatments. The Medications is further studied across Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, and Semaglutide. The Treatments is further studied across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery.
• Based on End-use, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of obesity and related disorder
    • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
    • 5.1.1.3. Introduction of novel anti-obesity drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing clinical trials and research & development activities
    • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
  • 5.1.4. Challenges
    • 5.1.4.1. Limited of knowledge regarding weight management
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Obesity Therapeutics Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medications
  • 6.2.1. Bupropion-naltrexone
  • 6.2.2. Liraglutide
  • 6.2.3. Orlistat
  • 6.2.4. Phentermine-topiramate
  • 6.2.5. Semaglutide
• 6.3. Treatments
  • 6.3.1. Adjustable Gastric Banding
  • 6.3.2. Endoscopic Sleeve Gastroplasty
  • 6.3.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

• 7.1. Introduction
• 7.2. Ambulatory Surgical Centers
• 7.3. Hospitals
• 7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Boehringer Ingelheim International GmbH
• 2. Bristol-Myers Squibb Company
• 3. Currax Pharmaceuticals LLC
• 4. Eisai Co., Ltd.
• 5. Eli Lilly and Company
• 6. F. Hoffmann-La Roche Ltd.
• 7. GlaxoSmithKline PLC
• 8. Merck & Co., Inc.
• 9. Norgine B.V.
• 10. Novartis AG
• 11. Novo Nordisk A/S
• 12. Pfizer Inc.
• 13. Rhythm Pharmaceuticals, Inc.
• 14. SHIONOGI & Co., Ltd.
• 15. Takeda Pharmaceutical Company Limited
• 16. Vivus LLC